Physician profile
Don Perez
NPI 1003897638
$177,642.70
in general payments reported to CMS, 2019-2025
38 companies · $36K in 2025
The $36K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,867 · 2020: $9,950 · 2021: $1,646 · 2022: $47K · 2023: $50K · 2024: $31K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $107K · Food and Beverage: $7,211 · Travel and Lodging: $2,855 · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $107,325.00 |
| Food and Beverage | $7,211.34 |
| Travel and Lodging | $2,855.22 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $165,528.99 | 2020-2025 | Acthar |
| Cardinal Health 108 LLC | $1,575.00 | 2020 | |
| Alcon Vision LLC | $1,135.37 | 2019-2025 | Argos, Unity, Rocklatan |
| Sun Pharmaceutical Industries INC. | $1,073.80 | 2019-2025 | Cequa |
| Horizon Therapeutics Plc | $1,059.40 | 2019-2023 | Tepezza |
| Ani Pharmaceuticals, INC. | $760.38 | 2022-2025 | Purified Cortrophin Gel, Iluvien |
| Mallinckrodt Enterprises LLC | $635.88 | 2019 | |
| Alimera Sciences, INC. | $497.97 | 2019-2024 | Iluvien, Yutiq |
| Genentech USA, INC. | $420.98 | 2019-2025 | Susvimo, Vabysmo |
| Novartis Pharmaceuticals Corporation | $385.73 | 2019-2023 | |
| Oyster Point Pharma, INC. | $382.48 | 2022-2024 | Tyrvaya, Ryzumvi |
| Allergan, INC. | $379.01 | 2019-2022 | |
| New World Medical,INC. | $332.64 | 2023-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Bausch & Lomb Americas INC. | $327.42 | 2023-2025 | Xiidra, Miebo, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $307.15 | 2019-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $306.90 | 2021-2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $301.85 | 2019-2021 | |
| Amgen INC. | $300.96 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $279.30 | 2024-2025 | Xdemvy |
| Abbvie INC. | $262.28 | 2019-2025 | |
| Sight Sciences, INC. | $261.52 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Kala Pharmaceuticals, INC. | $142.20 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $140.05 | 2024-2025 | Syfovre |
| Astellas Pharma US INC | $120.26 | 2023-2025 | Izervay |
| Aerie Pharmaceuticals, INC. | $111.37 | 2019-2021 | |
| Harrow Eye, LLC | $80.00 | 2024 | Vevye, Flarex, Natacyn |
| Shire North American Group INC | $79.74 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $70.59 | 2020-2024 | Eylea Hd |
| Thea Pharma INC. | $67.91 | 2022-2023 | Iyuzeh |
| Ocular Therapeutix, INC. | $67.06 | 2021-2025 | Dextenza |
| Biotissue Holdings INC. | $60.37 | 2022-2025 | |
| Glaukos Corporation | $53.66 | 2020-2023 | |
| Carl Zeiss Meditec USA, INC. | $28.85 | 2025 | |
| Tearlab Corp | $26.12 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $21.64 | 2021 | |
| Neurotech Pharmaceuticals, INC. | $21.17 | 2025 | |
| Ivantis, INC | $20.08 | 2020 | |
| Iridex Corporation | $16.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.